The goal of the Career Development Program is to enhance endometrial cancer research by providing financial support and mentoring for investigators new to the field. The Program will recruit both junior faculty and established investigators who are transitioning into endometrial cancer research. Highly qualified individuals will receive Career Development awards that will help support their endometrial cancer research. There will be a major emphasis on translational research, and the Career Development Program will ensure that its new investigators are mentored by both clinical and laboratory scientists. The Career Development Program will select awardees from the collaborating SPORE institutions and as the program matures, from other appropriately qualified institutions. Financial support (salary and research supply monies) will be provided for a period of up to two years. The Program will facilitate interactions between Career Development awardees and all members ofthe SPORE, emphasizing the basic and clinical science crossfertilization that is central to translational research. The Siteman Cancer Center, Washington University and our collaborating SPORE institutions provide outstanding opportunities for career development in endometrial cancer research. We have the ongoing research, evolving new collaborations, clinical programs in endometrial cancer and SPORE Project and Core Leaders experienced in mentoring trainees necessary for a Career Development Program's success. This program will be open to all institutions participating in the SPORE. We will specifically seek out underrepresented minority faculty to participate in the program. This program along with the Developmental Research Program is specifically committed to the recruitment of minority investigators. A Career Development Program Committee of senior faculty has been established. Kelle Moley, MD, chairs the committee that works with the SPORE principal investigators, project leaders and administrative staff to provide support to new investigators. This program will be funded jointly through the SPORE budget and a contribution of $125,000 per year from the Siteman Cancer Center, see letter of support from Dr Eberiein in Section X. Program Description and Section N ofthis program.

Public Health Relevance

The work proposed will lead to both an improved understanding of endometrial cancer biology and new approaches to the detection, prevention and treatment of uterine cancers which will result in reduced cancer morbidity and mortality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA134254-01A1
Application #
7727374
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2009-09-18
Project End
2012-08-31
Budget Start
2009-09-18
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$23,671
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Cosgrove, Casey M; Tritchler, David L; Cohn, David E et al. (2018) An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 148:174-180
Li, Jing; Xing, Xiaoyun; Li, Daofeng et al. (2017) Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. Neoplasia 19:100-111
Jeske, Yvette W; Ali, Shamshad; Byron, Sara A et al. (2017) FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 145:366-373
McMeekin, D Scott; Tritchler, David L; Cohn, David E et al. (2016) Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 34:3062-8
Rocconi, Rodney P; Lankes, Heather A; Brady, William E et al. (2016) The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 140:264-9
Goodfellow, Paul J; Billingsley, Caroline C; Lankes, Heather A et al. (2015) Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol 33:4301-8
Frolova, Antonina I; Babb, Sheri A; Zantow, Emily et al. (2015) Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. Gynecol Oncol 137:7-13
Huang, Yi-Wen; Kuo, Chieh-Ti; Chen, Jo-Hsin et al. (2014) Hypermethylation of miR-203 in endometrial carcinomas. Gynecol Oncol 133:340-5
Powell, Matthew A; Sill, Michael W; Goodfellow, Paul J et al. (2014) A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:38-43
Wang, Li-Shu; Burke, Carol A; Hasson, Henrietta et al. (2014) A phase Ib study of the effects of black raspberries on rectal polyps in patients with familial adenomatous polyposis. Cancer Prev Res (Phila) 7:666-74

Showing the most recent 10 out of 34 publications